A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: Results from a 12-month follow-up

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 165-172

  Ko, D Y ^a   Kim, K H ^a   Song, K H ^a  

^a Dong A University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; PORPHYRIN; AMINOLEVULINIC ACID; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ADULT; AGED; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTICLE; ASIAN; BOWEN DISEASE; BURNING SENSATION; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERBIUM YAG LASER; ERYTHEMA; ESTHETICS; FEMALE; FLUORESCENCE; FOLLOW UP; GAUZE DRESSING; HUMAN; ILLUMINATION; LASER COAGULATION; LASER SURGERY; LIGHT EMITTING DIODE; MALE; MIDDLE AGED; OCCLUSIVE DRESSING; PAIN ASSESSMENT; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RED LIGHT; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ABLATION; ULTRAVIOLET RADIATION; VERY ELDERLY; VISUAL ANALOG SCALE; WOOD LAMP; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BOWEN'S DISEASE; COMPARATIVE STUDY; ETHNOLOGY; LOW LEVEL LASER THERAPY; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PROCEDURES; PROSPECTIVE STUDY; SKIN NEOPLASMS; SOLID STATE LASER; THERAPEUTIC USE;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; ASIAN CONTINENTAL ANCESTRY GROUP; BOWEN'S DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASER THERAPY; LASERS, SOLID-STATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84887916718     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12627     Document Type: Article

References (36)

1. Bowen JT,. Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. J Cutan Dis 1912; 30: 241-55.
2. Cox NH, Eedy DJ, Morton CA,. Guidelines for management of Bowen's disease. Br J Dermatol 1999; 141: 633-41.
3. Slaper H, Velders GJM, Daniel JS, et al,. Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements. Nature 1996; 384: 256-8.
4. Eedy DJ, Gavin AT,. Thirteen-year retrospective study of Bowen's disease in Northern Ireland. Br J Dermatol 1987; 117: 715-20.
5. Cox NH,. Body site distribution of Bowen's disease. Br J Dermatol 1994; 130: 714-16.
6. Kao GF,. Carcinoma arising in Bowen's disease. Arch Dermatol 1986; 122: 1124-6.
7. Cox NH, Eedy DJ, Morton CA,; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 2007; 156: 11-21.
8. Ahmed I, Berth-Jones J, Charles-Holmes S, et al,. Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study. Br J Dermatol 2000; 143: 759-66.
9. Stone N, Burge S,. Bowen's disease of the leg treated with weekly pulses of 5% fluorouracil cream. Br J Dermatol 1999; 140: 987-8.
10. Patel GK, Goodwin R, Chawla M, et al,. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54: 1025-32.
11. Hsi RA, Rosenthal DI, Glatstein E,. Photodynamic therapy in the treatment of cancer. Drugs 1999; 57: 725-34.
12. Angell-Petersen E, Sorensen R, Warloe T, et al,. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006; 126: 265-71.
13. Peng Q, Moan J, Warloe T, et al,. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996; 34: 95-6.
14. Kloek J, Beijersbergen van Henegouwen GMJ,. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 1996; 64: 994-1000.
15. Fritsch C, Homey B, Stahl W, et al,. Preferential relative porphyrin enrichment in solar keratoses upon topical application of 5-aminolevulinic acid methylester. Photochem Photobiol 1998; 68: 218-21.
16. Arlette JP, Trotter MJ,. Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment. Australas J Dermatol 2004; 45: 1-11.
17. Morton C, McKenna KE, Rhodes LE,. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-66.
18. Mikszta JA, Alarcon JB, Brittingham JM, et al,. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8: 415-19.
19. Goldberg DJ, Berlin AL, Phelps R,. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med 2008; 40: 134-8.
20. 2 laser-assisted drug delivery. Lasers Surg Med 2010; 42: 113-22.
21. 2 laser pretreatment. Lasers Surg Med 2011; 43: 804-13.
22. McCarthy M Jr, Chang CH, Pickard AS, et al,. Visual analog scales for assessing surgical pain. J Am Coll Surg 2005; 201: 245-52.
23. Morton CA, Horn M, Leman J, et al,. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729-35.
24. Morton C, Horn M, Lehman J, et al,. A 24-month update of a placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluorouracil in patients with Bowen's disease. J Eur Acad Dermatol Venereol 2005; 19 (Suppl. 2): 237-8.
25. Calzavara-Pinton PG, Venturini M, Sala R, et al,. Methylaminolaevulinate- based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008; 159: 137-44.
26. Lõpez N, Meyer-Gonzalez T, Herrera-Acosta E, et al,. Photodynamic therapy in the treatment of extensive Bowen's disease. J Dermatolog Treat 2012; 23: 428-30.
27. Mizutani K, Akita Y, Yanagishita T, et al,. Comparison of the efficacy of ALA-PDT using an excimer-dye laser (630 nm) and a metal-halide lamp (600 to 740 nm) for treatment of Bowen's disease. Photodermatol Photoimmunol Photomed 2012; 28: 142-6.
28. Kim YJ, Kang HY, Lee ES, Kim YC,. Photodynamic therapy for treatment of Bowen's disease. Korean J Dermatol 2007; 45: 237-41.
29. Matsumoto Y, Akita Y, Nakaseko H, et al,. Clinical responses to topical photodynamic therapy of actinic keratoses, Bowen's disease and non-oncological disease in Japan. Laser Therapy 2010; 19: 159-66.
30. Gerritsen MJ, Smits T, Kleinpenning MM, et al,. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.
31. Ma LW, Nielsen KP, Iani V, Moan J,. A new method for photodynamic therapy of melanotic melanoma-effects of depigmentation with violet light photodynamic therapy. J Environ Pathol Toxicol Oncol 2007; 26: 165-72.
32. Shen SC, Lee WR, Fang YP, et al,. In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolaevulinic acid application with enhancement using an erbium:YAG laser. J Pharm Sci 2006; 95: 929-38.
33. Forster B, Klein A, Szeimies RM, Maisch T,. Penetration enhancement of two topical 5-aminolaevulinic acid formulations for photodynamic therapy by erbium:YAG laser ablation of the stratum corneum: continuous versus fractional ablation. Exp Dermatol 2010; 19: 806-12.
34. Metelitsa AI, Alster TS,. Fractionated laser skin resurfacing treatment complications: a review. Dermatol Surg 2010; 36: 299-306.
35. 2 and Er:YAG): a randomized controlled double-blind split-face trial of the treatment of peri-orbital rhytides. Lasers Surg Med 2010; 42: 160-7.
36. Smucler R, Vlk M,. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med 2008; 40: 153-8.